Moderna, Inc.

MRNA Healthcare Biotechnology

Moderna, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.9 billion, down 39.9% from fiscal 2024. In the quarter to June 2026, revenue grew 2.11%, EPS grew 7.51%, free cash flow grew 38.9% and total debt rose 1,765.6%, each against the same quarter a year earlier. Member of the S&P 500 and Nasdaq 100.

218.01 18.49 −7.82%
Market cap
$94.4B
P/E
0.0×
Fwd P/E
−5.5×
Dividend yield
—
F-score
3/9
Altman Z
2.46
Beneish M
−3.52
Dividend safety
n/a

Moderna, Inc. (MRNA) Operating margin

Alert me on Operating margin

Moderna, Inc.'s operating margin over the twelve months to 30 June 2026 was −149.0%, up 9.1 percentage points from fiscal 2025 (−158.1%). Over the past ten years it has ranged from −910.0% (fiscal 2019) to 72.0% (fiscal 2021); the current reading is higher than 40% of that period. That is below the Biotechnology industry median of 0.00% and below the Healthcare sector median of 0.00%.

Operating margin, annual

Embed this chart

Annual newest first

Period Operating margin Change (points)
FY2025 −158.1% (36.22)
FY2024 −121.9% (60.01)
FY2023 −61.9% (110.80)
FY2022 48.9% (23.08)
FY2021 72.0% 167.00
FY2020 −95.0% 814.98
FY2019 −910.0% (604.03)
FY2018 −306.0% (175.10)
FY2017 −130.9% 75.57
FY2016 −206.4% —

Quarterly newest first

Period Operating margin Change (points)
Jun 2026 −562.1% (205.26)
Mar 2026 −356.8% (230.41)
Dec 2025 −126.4% (100.81)
Sep 2025 −25.6% 613.14
30 more quarters

Against its own ten years

Low −910.0% High 72.0%
Ten-year median −126.4%
Current reading's percentile 39

Operating margin against peers

What Operating margin is

EBIT Margin tells an investor how much operating profit, before interest and taxes, a company keeps from each unit of revenue.

EBIT ÷ Revenue

The full definition of Operating margin →

More on MRNA